GCP
IMUX icon

GSA Capital Partners’s Immunic IMUX Stock Holding History

GSA Capital Partners’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-52,746
Closed -$282K – 1931
2025
Q4 		$282K Buy
52,746
+33,454
+173% +$245K 0.02% 1206
2025
Q3 		$170K Buy
+19,292
New +$170K 0.01% 1463
2025
Q2 		– Sell
-17,738
Closed -$193K – 1931
2025
Q1 		$193K Buy
17,738
+6,144
+53% +$66.3K 0.02% 1402
2024
Q4 		$116K Buy
11,594
+8,317
+254% +$105K 0.01% 1501
2024
Q3 		$54K Sell
3,277
-8,400
-72% -$120K ﹤0.01% 1519
2024
Q2 		$130K Buy
+11,677
New +$145K 0.01% 1505
2023
Q1 		– Sell
-7,919
Closed -$111K – 1684
2022
Q4 		$111K Buy
7,919
+4,947
+166% +$135K 0.01% 1293
2022
Q3 		$94K Buy
+2,972
New +$124K 0.01% 1369
2019
Q2 		– Sell
-1,009
Closed -$80K – 1571
2019
Q1 		$80K Buy
1,009
+877
+664% +$77K 0.01% 1343
2018
Q4 		$10K Buy
+132
New +$15.5K ﹤0.01% 1290

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

GSA Capital Partners's IMUX Position: Q1 2026 in Review

GSA Capital Partners sold out of Immunic (IMUX) in Q1 2026, closing a stake of 52,746 shares — an estimated $282K sold.

GSA Capital Partners first reported a position in IMUX in Q4 2018 and held it in 10 quarters. The position peaked at $282K in Q4 2025. 75 funds tracked by Wall St. Rank hold IMUX as of Q1 2026.

  • GSA Capital Partners reported no remaining Immunic position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 52,746 Immunic shares in Q1 2026, an estimated $282K.
  • GSA Capital Partners first reported a position in Immunic in Q4 2018 and held it in 10 quarters.
  • GSA Capital Partners's Immunic position peaked at $282K in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Immunic as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.